Looking ahead, it's my expectation that the forthcoming therapeutic products bill will enable medicines, including vaccines, to be rolled out in a timely and flexible manner. In the meantime, this bill will help us to manage to the ongoing public health risk of COVID-19. It does this by providing for the ongoing delivery of the third or "booster" doses at the reduced dose interval, providing fourth doses for our most at risk, and ensuring that we can easily roll out further doses should they be required in the future.